Key Insights

Highlights

Success Rate

78% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.2%

6 terminated out of 73 trials

Success Rate

77.8%

-8.7% vs benchmark

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

38%

8 of 21 completed with results

Key Signals

8 with results78% success

Data Visualizations

Phase Distribution

61Total
Not Applicable (23)
Early P 1 (4)
P 1 (20)
P 2 (12)
P 3 (2)

Trial Status

Completed21
Recruiting18
Unknown12
Active Not Recruiting7
Terminated6
Withdrawn4

Trial Success Rate

77.8%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (73)

Showing 20 of 20 trials
NCT04239573Not ApplicableRecruitingPrimary

Comparing Two Methods to Follow Patients With Pancreatic Cysts

NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT06723236Phase 1Recruiting

A Study of MGC028 in Participants With Advanced Solid Tumors

NCT06271291RecruitingPrimary

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

NCT06799637Phase 1Recruiting

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

NCT06807437Phase 3RecruitingPrimary

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

NCT02676349Phase 2CompletedPrimary

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

NCT04905082Not ApplicableActive Not Recruiting

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

NCT03164486Early Phase 1Active Not Recruiting

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

NCT05642962Phase 1Active Not Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05497531Not ApplicableRecruiting

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

NCT02432963Phase 1Active Not Recruiting

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

NCT06172478Phase 2Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT07359586Recruiting

Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia

NCT04505553Phase 2Completed

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

NCT06168812Phase 2Active Not Recruiting

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

NCT06115499Phase 2Active Not Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

NCT03745794Phase 2CompletedPrimary

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT06388967Recruiting

Pancreatic Cancer Detection Consortium

Scroll to load more

Research Network

Activity Timeline